The Second Edition of
A-Z of Neurological Practice
builds on the previous edition with
revised and updated information in a high density but easily accessible format to provide a quick and ready reference for busy clinicians of all degrees of experience. Entries for specific neurological conditions are uniformly structured indicating: Pathophysiology; Clinical Features; Investigations and Diagnosis; Differential Diagnosis; Treatment and Prognosis. Key references are cited throughout and all entries are cross referenced.
A-Z of Neurological Practice, Second Edition
is a practical, authoritative guide that will become an invaluable resource for neurologists in clinical practice, neurology trainees and all those involved with the treatment of neurological disorders.
Inhaltsverzeichnis
1;A-Z of Neurological Practice;3 1.1;Copyright Page;4 1.2;Preface to the Second Edition;5 1.3;A;7 1.3.1;Abetalipoproteinemia [OMIM#200100];7 1.3.1.1;Clinical features;7 1.3.1.2;Investigation;8 1.3.1.3;Differential diagnosis;8 1.3.1.4;Treatment and prognosis;8 1.3.2;Abscess: overview;9 1.3.3;Acanthamoeba;10 1.3.4;Aceruloplasminemia [OMIM#604290];11 1.3.5;Achondroplasia [OMIM#100800];11 1.3.6;Acromegaly;12 1.3.7;Actinomycosis;12 1.3.8;Action myoclonusrenal failure syndrome (AMRF) [OMIM#254900];13 1.3.8.1;Clinical features;13 1.3.8.2;Investigation;13 1.3.8.3;Differential diagnosis;13 1.3.8.4;Treatment and prognosis;14 1.3.9;Acute disseminated encephalomyelitis (ADEM);14 1.3.9.1;Clinical features;14 1.3.9.2;Investigation;15 1.3.9.3;Differential diagnosis;15 1.3.9.4;Treatment and prognosis;16 1.3.10;Adrenoleukodystrophy (X-ALD) [OMIM#300100];16 1.3.10.1;Clinical features;17 1.3.10.2;Investigation;17 1.3.10.3;Differential diagnosis;18 1.3.10.4;Treatment and prognosis;18 1.3.11;AlbersSchönberg disease;19 1.3.12;Alcohol and the nervous system: overview;19 1.3.12.1;Clinical features;19 1.3.12.2;Treatment and prognosis;21 1.3.13;Alexanders disease [OMIM#203450];22 1.3.13.1;Clinical features;22 1.3.13.2;Investigation;22 1.3.13.3;Differential diagnosis;22 1.3.13.4;Treatment and prognosis;23 1.3.14;Altitude illness;23 1.3.14.1;Clinical features;23 1.3.14.2;Treatment and prognosis;24 1.3.15;Alzheimers disease (AD);24 1.3.15.1;Clinical features;25 1.3.15.2;Investigation;27 1.3.15.3;Differential diagnosis;28 1.3.15.4;Treatment and prognosis;28 1.3.16;Aminoacidopathies: overview;29 1.3.16.1;Investigation;30 1.3.17;Amoebic infection: overview;31 1.3.18;Amyloid diseases: overview;31 1.3.19;AndersenTawil syndrome [OMIM#170390];32 1.3.20;Aneurysm: overview;32 1.3.20.1;Clinical features;33 1.3.20.2;Investigation;33 1.3.20.3;Treatment and prognosis;34 1.3.21;Angelman syndrome [OMIM#105830];34 1.3.21.1;Clinical features;34 1.3.21.2;Investigation;35 1.3.21.3;Differential diagnosis;35 1.3.21
.4;Treatment and prognosis;35 1.3.22;Angiostrongyliasis;35 1.3.23;Ankylosing spondylitis;36 1.3.23.1;Clinical features;36 1.3.23.2;Investigation;37 1.3.23.3;Differential diagnosis;37 1.3.23.4;Treatment and prognosis;37 1.3.24;Anterior choroidal artery infarction;38 1.3.25;Anterior interosseous neuropathy;38 1.3.26;Anterior spinal artery syndrome (ASAS);39 1.3.26.1;Clinical features;40 1.3.26.2;Investigation;40 1.3.26.3;Treatment and prognosis;40 1.3.27;Anthrax;40 1.3.27.1;Clinical features;40 1.3.27.2;Investigation;41 1.3.27.3;Differential diagnosis;41 1.3.27.4;Treatment and prognosis;41 1.3.28;Antiphospholipid syndrome (APS);41 1.3.28.1;Clinical features;42 1.3.28.2;Investigation;42 1.3.28.3;Differential diagnosis;42 1.3.28.4;Treatment and prognosis;43 1.3.29;AntonBabinski syndrome;43 1.3.30;Arachnoid cyst;43 1.3.30.1;Clinical features;44 1.3.30.2;Investigation;44 1.3.30.3;Differential diagnosis;44 1.3.30.4;Treatment and prognosis;44 1.3.31;Arachnoiditis;44 1.3.31.1;Clinical features;45 1.3.31.2;Investigation;45 1.3.31.3;Differential diagnosis;46 1.3.31.4;Treatment and prognosis;46 1.3.32;Arbovirus disease: overview;46 1.3.33;Argyrophilic grain disease (AGD);47 1.3.34;Arteriovenous malformations (AVMs);47 1.3.34.1;Clinical features;47 1.3.34.2;Investigation;48 1.3.34.3;Differential diagnosis;48 1.3.34.4;Treatment and prognosis;48 1.3.35;Aseptic meningitis: overview;49 1.3.36;Aspergillosis;49 1.3.37;Astrocytoma;50 1.3.38;Ataxia telangiectasia (AT) [OMIM#208900];50 1.3.38.1;Clinical features;51 1.3.38.2;Investigation;51 1.3.38.3;Differential diagnosis;52 1.3.38.4;Treatment and prognosis;52 1.3.39;Ataxia with isolated vitamin E deficiency (AVED) [OMIM#277460];52 1.3.40;Ataxia with oculomotor apraxia (AOA);53 1.3.41;Atlantoaxial dislocation, subluxation;54 1.3.42;Atypical facial pain;54 1.3.43;Atypical pneumonias: overview;54 1.3.44;Autonomic failure: overview;55 1.3.44.1;Clinical features;56 1.3.44.2;Investigation;56 1.3.44.3;Treatment and prognosis;57 1.3.45;Autosoma
l dominant cerebellar ataxia (ADCA): overview;58 1.3.46;Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) [OMIM#600513, #605375];59 1.3.46.1;Clinical features;60 1.3.46.2;Investigation;60 1.3.46.3;Differential diagnosis;60 1.3.46.4;Treatment and prognosis;60 1.4;B;61 1.4.1;Balòs concentric sclerosis;61 1.4.2;Barth syndrome;61 1.4.3;Bartonellosis;62 1.4.4;Basal ganglia calcification: overview;62 1.4.5;Basedows paraplegia;63 1.4.6;Becker muscular dystrophy (BMD) [OMIM#300376];64 1.4.7;Behçets disease;64 1.4.7.1;Clinical features;65 1.4.7.2;Investigation;65 1.4.7.3;Differential diagnosis;66 1.4.7.4;Treatment and prognosis;66 1.4.7.5;Diagnostic criteria;67 1.4.7.6;Reference;67 1.4.8;Behr syndrome;67 1.4.9;Bells palsy;68 1.4.9.1;Clinical features;68 1.4.9.2;Investigation;69 1.4.9.3;Differential diagnosis;69 1.4.9.4;Treatment and prognosis;69 1.4.10;Belly dancers dyskinesia;70 1.4.11;Benign epilepsy syndromes: overview;71 1.4.12;Benign hereditary chorea (BHC) [OMIM#118700];71 1.4.13;Benign paroxysmal positional vertigo (BPPV);72 1.4.13.1;Clinical features;72 1.4.13.2;Investigation;73 1.4.13.3;Differential diagnosis;73 1.4.13.4;Treatment and prognosis;73 1.4.14;Beriberi;74 1.4.14.1;Clinical features;74 1.4.14.2;Investigation;75 1.4.14.3;Differential diagnosis;75 1.4.14.4;Treatment and prognosis;75 1.4.15;Bethlem myopathy [OMIM#158810];76 1.4.16;Bickerstaffs brainstem encephalitis (BBE);76 1.4.16.1;Clinical features;77 1.4.16.2;Investigation;77 1.4.16.3;Differential diagnosis;77 1.4.16.4;Treatment and prognosis;77 1.4.17;BingNeel syndrome;78 1.4.18;Binswangers disease;78 1.4.18.1;Clinical features;79 1.4.18.2;Investigation;79 1.4.18.3;Differential diagnosis;79 1.4.18.4;Treatment and prognosis;80 1.4.19;Blastomycosis;80 1.4.20;Blue rubber bleb naevus syndrome;80 1.4.21;Botulism;81 1.4.21.1;Clinical features;81 1.4.21.2;Investigation;82 1.4.21.3;Differential diagnosis;82 1.4.21.4;Treatment and prognosis;82 1.4.22;BoucherNeuhauser syndrome;83 1.4.23;Brachial plexopat
hy: overview;83 1.4.23.1;Clinical features;84 1.4.23.2;Investigation;84 1.4.23.3;Differential diagnosis;85 1.4.23.4;Treatment and prognosis;85 1.4.24;Brain death;85 1.4.24.1;Clinical features;86 1.4.24.2;Investigation;87 1.4.24.3;Differential diagnosis;87 1.4.24.4;Treatment and prognosis;87 1.4.25;Brain stem vascular syndromes: overview;87 1.4.26;Brody disease [OMIM#601003];90 1.4.27;Browns syndrome;91 1.4.28;BrownVialettovan Laere syndrome;91 1.4.29;Burning mouth syndrome;92 1.5;C;93 1.5.1;CADASIL;93 1.5.1.1;Clinical features;93 1.5.1.2;Investigation;93 1.5.1.3;Differential diagnosis;94 1.5.1.4;Treatment and prognosis;94 1.5.2;Caisson disease;94 1.5.3;Camptocormia;95 1.5.4;Camptodactyly;95 1.5.4.1;Clinical features;95 1.5.4.2;Investigation;96 1.5.4.3;Differential diagnosis;96 1.5.4.4;Treatment and prognosis;96 1.5.5;Candidiasis;96 1.5.6;CANOMAD;96 1.5.7;Capsular warning syndrome;97 1.5.8;Carbon monoxide poisoning;97 1.5.9;Carnitine palmit(o)yltransferase (CPT) deficiency;98 1.5.9.1;Clinical features;99 1.5.9.2;Investigation;99 1.5.9.3;Differential diagnosis;99 1.5.9.4;Treatment and prognosis;99 1.5.10;Carotid artery disease: overview;100 1.5.10.1;Clinical features;100 1.5.10.2;Investigation;100 1.5.10.3;Differential diagnosis;101 1.5.10.4;Treatment and prognosis;101 1.5.11;Carotid-cavernous fistula (CCF);101 1.5.11.1;Clinical features;102 1.5.11.2;Investigation;102 1.5.11.3;Differential diagnosis;102 1.5.11.4;Treatment and prognosis;102 1.5.12;Carpal tunnel syndrome (CTS);102 1.5.12.1;Clinical features;103 1.5.12.2;Investigation;104 1.5.12.3;Differential diagnosis;104 1.5.12.4;Treatment and prognosis;104 1.5.13;Cauda equina syndrome and conus medullaris syndrome: overview;104 1.5.13.1;Clinical features;105 1.5.13.2;Investigation;105 1.5.13.3;Differential diagnosis;105 1.5.13.4;Treatment and prognosis;106 1.5.14;Cavernoma, cavernous hemagioma [OMIM#116860];106 1.5.15;Cavernous sinus disease;107 1.5.15.1;Clinical features;107 1.5.15.2;Investigation;108 1.5.15.3;Diffe
rential diagnosis;108 1.5.15.4;Treatment and prognosis;108 1.5.16;Cayman disease;109 1.5.17;Central core disease [OMIM#117000];109 1.5.18;Central pontine and extrapontine myelinolysis (CPEPM);110 1.5.18.1;Clinical features;110 1.5.18.2;Investigation;111 1.5.18.3;Differential diagnosis;111 1.5.18.4;Treatment and prognosis;111 1.5.19;Cerebellar disease: overview;112 1.5.19.1;Clinical features;114 1.5.19.2;Investigation;115 1.5.20;Cerebellopontine angle syndrome;116 1.5.21;Cerebral amyloid angiopathy (CAA);116 1.5.21.1;Clinical features;117 1.5.21.2;Investigation;117 1.5.21.3;Differential diagnosis;117 1.5.21.4;Treatment and prognosis;117 1.5.22;Cerebral palsy (CP);118 1.5.22.1;Clinical features;118 1.5.22.2;Investigation;118 1.5.22.3;Differential diagnosis;119 1.5.22.4;Treatment and prognosis;120 1.5.23;Cerebral salt wasting (CSW) syndrome;120 1.5.24;Cerebrotendinous xanthomatosis (CTX) [OMIM#213700];121 1.5.24.1;Clinical features;121 1.5.24.2;Investigation;122 1.5.24.3;Treatment and prognosis;122 1.5.25;Cervical cord and root disease: overview;122 1.5.25.1;Clinical features;123 1.5.25.2;Investigation;125 1.5.25.3;Differential diagnosis;125 1.5.25.4;Treatment and prognosis;125 1.5.26;Cervical dystonia;126 1.5.26.1;Clinical features;126 1.5.26.2;Investigation;126 1.5.26.3;Differential diagnosis;126 1.5.26.4;Treatment and prognosis;127 1.5.27;Channelopathies: overview;127 1.5.28;CharcotMarieTooth (CMT) disease;128 1.5.28.1;Clinical features;130 1.5.28.2;Investigation;130 1.5.28.3;Differential diagnosis;130 1.5.28.4;Treatment and prognosis;131 1.5.29;CharlevoixSaguenay syndrome [OMIM#270550];131 1.5.30;Cheiralgia paresthetica;131 1.5.31;Cheiro-oral syndrome;132 1.5.32;Chemotherapy-induced neurological disorders;132 1.5.32.1;Clinical features;132 1.5.32.2;Investigation;133 1.5.32.3;Differential diagnosis;133 1.5.32.4;Treatment and prognosis;133 1.5.33;Chiari malformations;133 1.5.33.1;Clinical features;134 1.5.33.2;Investigation;134 1.5.33.3;Differential diagnosis;134 1.5
.33.4;Treatment and prognosis;135 1.5.34;Cholesteatoma;135 1.5.35;Cholesterol embolization syndrome;136 1.5.36;Chordoma;136 1.5.37;Choriocarcinoma;137 1.5.38;Choroid plexus papilloma;137 1.5.39;Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP);137 1.5.39.1;Clinical features;137 1.5.39.2;Investigation;138 1.5.39.3;Differential diagnosis;139 1.5.39.4;Treatment and prognosis;139 1.5.40;Chronic progressive external ophthalmoplegia (CPEO);140 1.5.40.1;Clinical features;140 1.5.40.2;Investigation;140 1.5.40.3;Differential diagnosis;141 1.5.40.4;Treatment and prognosis;141 1.5.41;Chronic relapsing inflammatory optic neuropathy (CRION);141 1.5.42;ChurgStrauss syndrome;142 1.5.43;Ciguatera;142 1.5.44;Cluster headache (CH);143 1.5.44.1;Clinical features;143 1.5.44.2;Investigation;144 1.5.44.3;Differential diagnosis;144 1.5.44.4;Treatment and prognosis;144 1.5.45;Coarctation of the aorta;145 1.5.46;Cobb syndrome;146 1.5.47;Cocaine;146 1.5.48;Coccidioidomycosis;146 1.5.49;Coeliac disease;147 1.5.50;Coenurosis;148 1.5.51;Cogan syndrome (1);148 1.5.52;Cogan syndrome (2);149 1.5.53;Collagen vascular disorders and the nervous system: overview;149 1.5.54;Colloid cyst;150 1.5.55;Coma: overview;150 1.5.55.1;Clinical features;151 1.5.55.2;Investigation;151 1.5.55.3;Differential diagnosis;151 1.5.55.4;Treatment and prognosis;151 1.5.56;Common variable immunodeficiency (CVID);152 1.5.57;Compartment syndromes;152 1.5.58;Complex regional pain syndromes;153 1.5.58.1;Sec144_3;153 1.5.58.1.1;Clinical features;153 1.5.58.2;Investigation;153 1.5.58.3;Differential diagnosis;153 1.5.58.4;Treatment and prognosis;153 1.5.59;Congenital cranial dysinnervation disorders (CCDDs): overview;154 1.5.60;Congenital insensitivity to pain;155 1.5.61;Congenital muscle and neuromuscular disorders: overview;155 1.5.62;Congenital muscular dystrophies: overview;156 1.5.63;Congenital myasthenic syndromes: overview;157 1.5.63.1;Investigation;157 1.5.63.2;Differential diagnosis;158 1.5.63.3;Treatment a
nd prognosis;158 1.5.64;Copper deficiency-associated myeloneuropathy;158 1.5.65;Corticobasal degeneration (CBD);159 1.5.65.1;Clinical features;159 1.5.65.2;Investigation;160 1.5.65.3;Differential diagnosis;160 1.5.65.4;Treatment and prognosis;160 1.5.66;Cough headache;161 1.5.67;Cramp fasciculation syndrome;162 1.5.68;Cranial polyneuropathy;162 1.5.68.1;Investigation;163 1.5.69;Craniopharyngioma;163 1.5.69.1;Clinical features;163 1.5.69.2;Investigation;164 1.5.69.3;Differential diagnosis;164 1.5.69.4;Treatment and prognosis;164 1.5.70;CreutzfeldtJakob disease (CJD);164 1.5.70.1;Clinical features;164 1.5.70.2;Investigation;165 1.5.70.3;Differential diagnosis;166 1.5.70.4;Treatment and prognosis;166 1.5.71;Critical illness myopathy, critical illness polyneuropathy;166 1.5.72;Cryoglobulinemia, cryoglobulinemic neuropathy;167 1.5.73;Cryptococcosis;167 1.5.73.1;Clinical features;168 1.5.73.2;Investigation;168 1.5.73.3;Differential diagnosis;168 1.5.73.4;Treatment and prognosis;168 1.5.74;Cubital tunnel syndrome;169 1.5.74.1;Clinical features;169 1.5.74.2;Investigation;169 1.5.74.3;Treatment and prognosis;169 1.5.75;Cyanide poisoning;169 1.5.76;Cysts: overview;170 1.5.76.1;Investigations;170 1.5.76.2;Differential diagnosis;170 1.5.76.3;Treatment and prognosis;171 1.5.77;Cytomegalovirus (CMV) infection: overview;171 1.6;D;172 1.6.1;DandyWalker syndrome;172 1.6.2;Danon disease [OMIM#300257];172 1.6.3;Dawidenkow syndrome;173 1.6.4;Deafferentation pain syndrome;173 1.6.5;Degos Disease;173 1.6.6;DéjerineMouzon syndrome;174 1.6.7;DéjerineRoussy syndrome;174 1.6.8;DéjerineSottas syndrome (DSS) [OMIM#145900];175 1.6.9;Delirium: overview;175 1.6.9.1;Clinical features;177 1.6.9.2;Investigation;177 1.6.9.3;Differential diagnosis;177 1.6.9.4;Treatment and prognosis;178 1.6.10;Dementia: overview;178 1.6.10.1;Clinical features;181 1.6.10.2;Investigation;181 1.6.10.3;Differential diagnosis;182 1.6.10.4;Treatment and prognosis;182 1.6.11;Dementia with Lewy bodies (DLB);182 1.6.11.1;Clini
cal features;183 1.6.11.2;Investigation;183 1.6.11.3;Differential diagnosis;184 1.6.11.4;Treatment and prognosis;184 1.6.12;Dementia pugilistica;184 1.6.13;Demyelinating diseases of the nervous system: overview;185 1.6.14;Dengue;186 1.6.15;Dentatorubral-pallidoluysian atrophy (DRPLA) [OMIM#125370];186 1.6.15.1;Clinical features;187 1.6.15.2;Investigation;187 1.6.15.3;Differential diagnosis;187 1.6.15.4;Treatment and prognosis;187 1.6.16;Dermatomyositis;188 1.6.16.1;Clinical features;188 1.6.16.2;Investigation;189 1.6.16.3;Differential diagnosis;190 1.6.16.4;Treatment and prognosis;190 1.6.17;Dermoid;190 1.6.18;Desmin-related myopathy [OMIM#601419];191 1.6.19;Diabetes insipidus (DI);191 1.6.20;Diabetes mellitus and the nervous system: overview;192 1.6.20.1;Clinical features;192 1.6.20.2;Investigation;194 1.6.20.3;Treatment and prognosis;194 1.6.21;Dialysis syndromes;195 1.6.22;Diaphragmatic flutter;196 1.6.23;Diastematomyelia;196 1.6.24;Diogenes syndrome;197 1.6.25;Diphtheria;197 1.6.25.1;Clinical features;198 1.6.25.2;Investigation;198 1.6.25.3;Differential diagnosis;199 1.6.25.4;Treatment and prognosis;199 1.6.26;Diphyllobothriasis;199 1.6.27;Discitis;199 1.6.28;Disconnection syndromes;200 1.6.28.1;Clinical features;200 1.6.28.2;Investigation;201 1.6.28.3;Treatment and prognosis;201 1.6.29;Dissection: overview;201 1.6.29.1;Clinical features;202 1.6.29.2;Investigation;202 1.6.29.3;Differential diagnosis;202 1.6.29.4;Treatment and prognosis;202 1.6.30;Distal myopathy: overview;203 1.6.31;Dolichoectasia;204 1.6.32;Dopamine-b-hydroxylase deficiency [OMIM#223360];204 1.6.33;Dopa-responsive dystonia (DRD) [OMIM#128230];205 1.6.33.1;Clinical features;205 1.6.33.2;Investigation;205 1.6.33.3;Differential diagnosis;205 1.6.33.4;Treatment and prognosis;206 1.6.34;Down syndrome [OMIM#190685];206 1.6.35;Dracunculiasis;207 1.6.36;Drop attacks: overview;207 1.6.36.1;Investigation;209 1.6.36.2;Treatment and prognosis;209 1.6.37;Dropped head syndrome;209 1.6.38;Duanes syndrome;210
1.6.39;Duchenne muscular dystrophy (DMD) [OMIM#310200];210 1.6.39.1;Clinical features;211 1.6.39.2;Investigation;211 1.6.39.3;Differential diagnosis;211 1.6.39.4;Treatment and prognosis;211 1.6.40;Dural arteriovenous fistula (DAVF);212 1.6.40.1;Clinical features;212 1.6.40.2;Investigation;212 1.6.40.3;Differential diagnosis;213 1.6.40.4;Treatment and prognosis;213 1.6.41;Dysembryoplastic neuroepithelial tumor (DNET);213 1.6.42;Dysferlinopathy;214 1.6.43;Dystonia: overview;214 1.6.43.1;Investigation;219 1.6.43.2;Differential diagnosis;220 1.6.43.3;Treatment and prognosis;220 1.6.43.4;Treatment and prognosis;220 1.6.44;Dystrophinopathy;222 1.7;E;223 1.7.1;Eating disorders;223 1.7.2;Echinococcosis;224 1.7.3;Eclampsia;224 1.7.3.1;Clinical features;225 1.7.3.2;Investigation;225 1.7.3.3;Differential diagnosis;225 1.7.3.4;Treatment and prognosis;225 1.7.4;EhlersDanlos syndrome;226 1.7.5;Ehrlichiosis;226 1.7.6;Eighteen q deletion syndrome [OMIM#601808];227 1.7.7;Electrical injuries and the nervous system;227 1.7.8;Elsberg syndrome;228 1.7.9;EmeryDreifuss muscular dystrophy (EDMD);229 1.7.9.1;Clinical features;229 1.7.9.2;Investigation;229 1.7.9.3;Differential diagnosis;230 1.7.9.4;Treatment and prognosis;230 1.7.10;Empty sella syndrome;230 1.7.11;Encephalitis: overview;231 1.7.11.1;Clinical features;232 1.7.11.2;Investigation;233 1.7.11.3;Differential diagnosis;233 1.7.11.4;Treatment and prognosis;234 1.7.12;Encephalitis lethargica;234 1.7.13;Encephalopathies: overview;235 1.7.13.1;Clinical features;236 1.7.13.2;Investigation;236 1.7.13.3;Differential diagnosis;236 1.7.13.4;Treatment and prognosis;236 1.7.14;Endocarditis: overview;237 1.7.14.1;Clinical features;237 1.7.14.2;Investigation;238 1.7.14.3;Differential diagnosis;238 1.7.14.4;Treatment and prognosis;238 1.7.15;Endocrine disorders and neurology: overview;239 1.7.16;Entrapment neuropathies: overview;241 1.7.16.1;Investigation;242 1.7.16.2;Differential diagnosis;242 1.7.16.3;Treatment and prognosis;242 1.7.17;Eosinop
hilic syndromes: overview;243 1.7.18;Ependymoma;244 1.7.18.1;Clinical features;244 1.7.18.2;Investigation;245 1.7.18.3;Differential diagnosis;245 1.7.18.4;Treatment and prognosis;245 1.7.19;Epidermoid;245 1.7.20;Epilepsy: overview;246 1.7.20.1;Clinical features;247 1.7.20.2;Investigation;247 1.7.20.3;Differential diagnosis;248 1.7.20.4;Treatment and prognosis;248 1.7.21;Episodic ataxias;249 1.7.21.1;Clinical features;249 1.7.21.2;Investigation;250 1.7.21.3;Differential diagnosis;250 1.7.21.4;Treatment and prognosis;250 1.7.22;EpsteinBarr virus (EBV) infection and the nervous system: overview;250 1.7.23;Erbs palsy, Erb-Duchenne palsy;251 1.7.24;Erdheim-Chester disease;251 1.7.25;Essential tremor (ET);252 1.7.25.1;Clinical features;252 1.7.25.2;Investigation;253 1.7.25.3;Differential diagnosis;253 1.7.25.4;Treatment and prognosis;253 1.7.26;Exploding head syndrome;254 1.8;F;255 1.8.1;Fabrys disease [OMIM#301500];255 1.8.1.1;Clinical features;255 1.8.1.2;Investigation;256 1.8.1.3;Differential diagnosis;257 1.8.1.4;Treatment and prognosis;257 1.8.2;Facial pain: overview;257 1.8.2.1;Clinical features;258 1.8.2.2;Investigation;258 1.8.3;Facioscapulohumeral (FSH) muscular dystrophy [OMIM#158900];258 1.8.3.1;Clinical features;259 1.8.3.2;Investigation;259 1.8.3.3;Differential diagnosis;259 1.8.3.4;Treatment and prognosis;260 1.8.4;Fahrs disease;260 1.8.5;Familial amyloid polyneuropathies (FAP);261 1.8.5.1;Clinical features;261 1.8.5.2;Investigation;261 1.8.5.3;Differential diagnosis;262 1.8.5.4;Treatment and prognosis;262 1.8.6;Familial British dementia (FBD) [OMIM#176500];262 1.8.6.1;Clinical features;262 1.8.6.2;Investigations;263 1.8.6.3;Differential diagnosis;263 1.8.6.4;Treatment and prognosis;263 1.8.7;Familial Danish dementia (FDD) [OMIM#117300];263 1.8.8;Familial encephalopathy with neuroserpin inclusion bodies (FENIB) [OMIM#604218];264 1.8.9;Familial Mediterranean fever (FMF) [OMIM#249100];264 1.8.10;Familial periventricular heterotopia [OMIM#300049];265 1.8.11;Fat
embolism syndrome (FES);265 1.8.12;Fatal familial insomnia (FFI) [OMIM#600072];266 1.8.13;Fatty acid oxidation disorders (FAOD): overview;266 1.8.13.1;Clinical features;267 1.8.13.2;Investigation;267 1.8.13.3;Differential diagnosis;267 1.8.13.4;Treatment and prognosis;268 1.8.14;Febrile seizures;268 1.8.14.1;Clinical features;268 1.8.14.2;Investigation;269 1.8.14.3;Differential diagnosis;269 1.8.14.4;Treatment and prognosis;269 1.8.15;Femoral neuropathy;269 1.8.15.1;Clinical features;269 1.8.15.2;Investigation;270 1.8.15.3;Differential diagnosis;270 1.8.16;Fibromuscular dysplasia (FMD);270 1.8.16.1;Clinical features;270 1.8.16.2;Investigation;270 1.8.16.3;Differential diagnosis;271 1.8.16.4;Treatment and prognosis;271 1.8.17;Fibromyalgia syndrome (FMS);271 1.8.18;Fibrous dysplasia;272 1.8.19;Filariasis;272 1.8.20;Focal retrograde amnesia;272 1.8.21;FoixAlajouanine syndrome;272 1.8.22;FoixChavanyMarie syndrome;273 1.8.23;Foot drop: overview;273 1.8.23.1;Clinical features;274 1.8.23.2;Investigation;275 1.8.23.3;Differential diagnosis;275 1.8.23.4;Treatment and prognosis;275 1.8.24;Foramen magnum syndrome;275 1.8.24.1;Clinical features;276 1.8.24.2;Investigation;276 1.8.24.3;Treatment and prognosis;277 1.8.25;Fotopoulos syndrome;277 1.8.26;Fowlers syndrome;277 1.8.27;Fragile X syndromes (FRAX, FRAXE) [OMIM#300624; #309548];2781.8.28;Fragile X tremor ataxia syndrome (FXTAS) [OMIM#300623]279 1.8.29;Friedreichs ataxia (FA) [OMIM#229300];279 1.8.29.1;Clinical features;280 1.8.29.2;Investigation;280 1.8.29.3;Differential diagnosis;281 1.8.29.4;Treatment and prognosis;281 1.8.30;Froins syndrome;282 1.8.31;Frontotemporal lobar degeneration (FTLD);282 1.8.31.1;Clinical features;283 1.8.31.2;Investigation;283 1.8.31.3;Differential diagnosis;283 1.8.31.4;Treatment and prognosis;283 1.8.32;Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) [OMIM#600274, #607485];284 1.8.33;Fucosidosis [OMIM#230000];285 1.9;G;287 1.9.1;Gait disorders: overview;287 1.9.2;G
alloping tongue syndrome;289 1.9.3;Ganglioglioma;289 1.9.4;Gangliosidoses: overview;290 1.9.4.1;Clinical features;290 1.9.4.2;Investigation;291 1.9.4.3;Differential diagnosis;291 1.9.4.4;Treatment and prognosis;291 1.9.5;Garcin syndrome;292 1.9.6;Gardners syndrome;292 1.9.7;Gasperinis syndrome;292 1.9.8;Gastrointestinal disease and the nervous system: overview;293 1.9.8.1;Clinical features;293 1.9.8.2;Treatment and prognosis;293 1.9.9;Gauchers disease;294 1.9.9.1;Clinical features;294 1.9.9.2;Investigation;295 1.9.9.3;Differential diagnosis;295 1.9.9.4;Treatment and prognosis;295 1.9.10;Gelastic epilepsy;296 1.9.11;Gelsolin amyloidosis [OMIM#105120];296 1.9.12;Generalized epilepsy with febrile seizures plus (GEFS+) [OMIM#604233];297 1.9.13;Geniculate neuralgia;297 1.9.14;Geniospasm;298 1.9.15;Genitofemoral neuropathy;298 1.9.16;Gerhardt syndrome;298 1.9.17;Germ cell tumors;298 1.9.18;Germinoma;299 1.9.19;Gerstmann syndrome;300 1.9.20;GerstmannSträusslerScheinker disease (GSS) [OMIM#137440];300 1.9.21;Geschwind syndrome;300 1.9.22;Giant axonal neuropathy (GAN) [OMIM#256850];301 1.9.23;Giant cell arteritis (GCA);301 1.9.23.1;Clinical features;302 1.9.23.2;Investigation;302 1.9.23.3;Differential diagnosis;303 1.9.23.4;Treatment and prognosis;303 1.9.24;Glioma;304 1.9.24.1;Clinical features;304 1.9.24.2;Investigation;304 1.9.24.3;Differential diagnosis;305 1.9.24.4;Treatment and prognosis;305 1.9.25;Gliomatosis cerebri;306 1.9.26;Glomus jugulare tumor;306 1.9.26.1;Clinical features;306 1.9.26.2;Investigation;307 1.9.26.3;Differential diagnosis;307 1.9.26.4;Treatment and prognosis;307 1.9.27;Glossopharyngeal neuralgia;307 1.9.28;Glutaric acidurias;308 1.9.28.1;Clinical features;308 1.9.28.2;Investigation;309 1.9.28.3;Differential diagnosis;309 1.9.28.4;Treatment and prognosis;309 1.9.29;Glycogen storage disorders: overview;310 1.9.30;Gnathostomiasis;312 1.9.31;Godot syndrome;312 1.9.32;Godtfredsens syndrome;313 1.9.33;Gonyalgia paresthetica;313 1.9.34;Gourmand syndrome;3
13 1.9.35;Gradenigos syndrome;314 1.9.36;Grisel syndrome;314 1.9.37;Guam amyotrophic lateral sclerosis parkinsonismdementia complex (ALS/PDC);314 1.9.38;Guillain-Barré syndrome (GBS);315 1.9.38.1;Clinical features;316 1.9.38.2;Investigation;317 1.9.38.3;Differential diagnosis;317 1.9.38.4;Treatment and prognosis;318 1.10;H;319 1.10.1;Hematoma: overview;319 1.10.2;Hemochromatosis;319 1.10.3;Hardings syndrome;320 1.10.4;HARP syndrome [OMIM#607236];320 1.10.5;Hashimotos encephalopathy;321 1.10.6;Headache: overview;321 1.10.6.1;Clinical features;322 1.10.6.2;Investigation;323 1.10.6.3;Treatment and prognosis;323 1.10.7;Heatstroke;323 1.10.8;Heavy metal poisoning: overview;324 1.10.9;Helminthic diseases: overview;325 1.10.10;Hemifacial spasm (HFS);325 1.10.10.1;Clinical features;326 1.10.10.2;Investigation;326 1.10.10.3;Differential diagnosis;326 1.10.10.4;Treatment and prognosis;326 1.10.11;Hepatic encephalopathy;327 1.10.11.1;Portal-systemic encephalopathy;327 1.10.11.2;Clinical features;327 1.10.11.3;Investigation;327 1.10.11.4;Differential diagnosis;327 1.10.11.5;Treatment and prognosis;328 1.10.12;Hereditary fructose intolerance (HFI) [OMIM#229600];328 1.10.13;Hereditary hemorrhagic telangiectasia (HHT) [OMIM#187300];329 1.10.13.1;Familial telangiectasia, OslerWeberRendu syndrome, RenduOslerWeber syndrome;329 1.10.14;Hereditary motor and sensory neuropathy (HMSN);329 1.10.14.1;Clinical features;330 1.10.14.2;Investigation;330 1.10.14.3;Differential diagnosis;330 1.10.14.4;Treatment and prognosis;330 1.10.15;Hereditary motor neuropathy (HMN);331 1.10.16;Hereditary neuropathy with liability to pressure palsies (HNLPP) [OMIM#162500];332 1.10.17;Hereditary sensory and autonomic neuropathy (HSAN);332 1.10.18;Hereditary spastic paraplegia (HSP);333 1.10.18.1;Clinical features;335 1.10.18.2;Investigation;336 1.10.18.3;Differential diagnosis;336 1.10.18.4;Treatment and prognosis;336 1.10.19;HERNS;336 1.10.20;Heroin;337 1.10.21;Herpes simplex encephalitis (HSE);337 1.10.21.1
;Clinical features;338 1.10.21.2;Investigation;338 1.10.21.3;Differential diagnosis;339 1.10.21.4;Treatment and prognosis;339 1.10.22;Herpes zoster and postherpetic neuralgia;340 1.10.22.1;Clinical features;340 1.10.22.2;Investigation;340 1.10.22.3;Differential diagnosis;341 1.10.22.4;Treatment and prognosis;341 1.10.23;Heterotopias;341 1.10.24;Histoplasmosis;342 1.10.25;HIV/AIDS: overview;342 1.10.25.1;Clinical features;342 1.10.25.2;Investigation;343 1.10.25.3;Differential diagnosis;343 1.10.25.4;Treatment and prognosis;344 1.10.26;Hoffmans syndrome;344 1.10.27;HolmesAdie syndrome;345 1.10.28;Homocystinuria [OMIM#236200];345 1.10.28.1;Clinical features;345 1.10.28.2;Investigation;346 1.10.28.3;Differential diagnosis;346 1.10.28.4;Treatment and prognosis;346 1.10.29;Hopkins syndrome;347 1.10.30;HTLV-1 myelopathy;347 1.10.30.1;Clinical features;347 1.10.30.2;Investigation;347 1.10.30.3;Differential diagnosis;348 1.10.30.4;Treatment and prognosis;348 1.10.31;Huntingtons disease (HD) [OMIM#143100];348 1.10.31.1;Clinical features;348 1.10.31.2;Investigation;349 1.10.31.3;Differential diagnosis;349 1.10.31.4;Treatment and prognosis;350 1.10.32;Hydrocephalus: overview;350 1.10.32.1;Clinical features;351 1.10.32.2;Investigation;351 1.10.32.3;Differential diagnosis;351 1.10.32.4;Treatment and prognosis;351 1.10.33;Hyperekplexia;352 1.10.34;Hypereosinophilic syndrome (HES);352 1.10.35;Hyperostosis cranialis interna;353 1.10.36;Hypertension and the nervous system: overview;353 1.10.36.1;Clinical features;354 1.10.36.2;Investigation;354 1.10.36.3;Treatment and prognosis;354 1.10.37;Hypnic headache;355 1.10.38;Hypobetalipoproteinemia;355 1.10.39;Hypothalamic disease: overview;356 1.10.39.1;Clinical features;356 1.10.39.2;Investigation;356 1.10.39.3;Treatment and prognosis;356 1.11;I;357 1.11.1;Idiopathic hyperCKemia;357 1.11.2;Idiopathic hypersomnia;357 1.11.3;Idiopathic intracranial hypertension (IIH);358 1.11.3.1;Clinical features;358 1.11.3.2;Investigation;359 1.11.3.3;Diff
erential diagnosis;359 1.11.3.4;Treatment and prognosis;359 1.11.4;Ilioinguinal neuropathy;360 1.11.5;ImerslundGräsbeck syndrome;360 1.11.6;Inclusion body myositis (IBM);361 1.11.6.1;Clinical features;361 1.11.6.2;Investigation;361 1.11.6.3;Differential diagnosis;361 1.11.6.4;Treatment and prognosis;362 1.11.7;Incontinentia pigmenti (achromians);362 1.11.8;Intervertebral disc prolapse;363 1.11.8.1;Clinical features;363 1.11.8.2;Investigation;363 1.11.8.3;Differential diagnosis;364 1.11.8.4;Treatment and prognosis;364 1.11.9;Intracerebral hemorrhage (ICH);364 1.11.9.1;Clinical features;365 1.11.9.2;Investigation;365 1.11.9.3;Differential diagnosis;365 1.11.9.4;Treatment and prognosis;366 1.11.10;Intravascular lymphoma;366 1.11.10.1;Clinical features;367 1.11.10.2;Investigation;367 1.11.10.3;Differential diagnosis;367 1.11.10.4;Treatment and prognosis;367 1.11.11;Ischemic optic neuropathy (ION);368 1.11.11.1;Clinical features;368 1.11.11.2;Investigation;369 1.11.11.3;Differential diagnosis;369 1.11.11.4;Treatment and prognosis;369 1.12;J;370 1.12.1;Japanese encephalitis;370 1.12.1.1;Clinical features;370 1.12.1.2;Investigation;370 1.12.1.3;Differential diagnosis;371 1.12.1.4;Treatment and prognosis;371 1.12.2;Jeavons syndrome;371 1.12.3;Jugular foramen syndrome;372 1.12.3.1;Clinical features;372 1.12.3.2;Investigation;372 1.12.3.3;Differential diagnosis;373 1.12.3.4;Treatment and prognosis;373 1.12.4;Juvenile myoclonic epilepsy (JME);374 1.12.4.1;Clinical features;374 1.12.4.2;Investigation;374 1.12.4.3;Treatment and prognosis;374 1.13;K;375 1.13.1;Kallmanns syndrome;375 1.13.2;KearnsSayre syndrome (KSS);375 1.13.2.1;Clinical features;376 1.13.2.2;Investigation;376 1.13.2.3;Differential diagnosis;376 1.13.2.4;Treatment and prognosis;376 1.13.3;Kernohans syndrome;377 1.13.4;Kjellins syndrome;377 1.13.5;KleineLevin syndrome;378 1.13.6;KlippelFeil anomaly;378 1.13.7;KlippelTrénaunayWeber syndrome;379 1.13.8;Klumpkes palsy;379 1.13.9;KlüverBucy syndrome;379 1.13.10;Konzo;
380 1.13.11;Krabbes disease [OMIM#245200];381 1.13.11.1;Clinical features;381 1.13.11.2;Investigation;381 1.13.11.3;Differential diagnosis;381 1.13.11.4;Treatment and prognosis;382 1.13.12;Kufor-Rakeb disease [OMIM#606693];382 1.13.13;Kufs disease;382 1.13.13.1;Clinical features;383 1.13.13.2;Investigation;383 1.13.13.3;Differential diagnosis;383 1.13.13.4;Treatment and prognosis;383 1.13.14;KugelbergWelander disease;384 1.13.15;Kuru;384 1.14;L;385 1.14.1;l-2-Hydroxyglutaric acidemia [OMIM#236792];385 1.14.2;Lactic acidosis: overview;385 1.14.3;Lacunar syndromes (LACS);386 1.14.4;Lafora body disease [OMIM#254780];387 1.14.5;Laing myopathy [OMIM#160500];388 1.14.6;LambertEaton myasthenic syndrome (LEMS);388 1.14.6.1;Clinical features;388 1.14.6.2;Investigation;389 1.14.6.3;Differential diagnosis;389 1.14.6.4;Treatment and prognosis;389 1.14.7;LanceAdams syndrome;390 1.14.8;LandauKleffner syndrome;390 1.14.9;Langerhans cell histiocytosis (LCH);391 1.14.9.1;Clinical features;391 1.14.9.2;Investigation;391 1.14.9.3;Differential diagnosis;391 1.14.9.4;Treatment and prognosis;392 1.14.10;Lathyrism;392 1.14.11;Lead and the nervous system: Overview;392 1.14.11.1;Clinical features;392 1.14.11.2;Investigation;393 1.14.11.3;Differential diagnosis;393 1.14.11.4;Treatment and prognosis;393 1.14.12;Lebers hereditary optic neuropathy (LHON);393 1.14.12.1;Clinical features;394 1.14.12.2;Investigation;394 1.14.12.3;Differential diagnosis;394 1.14.12.4;Treatment and prognosis;394 1.14.13;Legionnaires disease;394 1.14.13.1;Clinical features;394 1.14.13.2;Investigation;395 1.14.14;Differential diagnosis;395 1.14.14.1;Treatment and prognosis;395 1.14.15;Leighs syndrome;395 1.14.15.1;Clinical features;396 1.14.15.2;Investigation;396 1.14.15.3;Differential diagnosis;396 1.14.15.4;Treatment and prognosis;397 1.14.16;Lemierres syndrome;397 1.14.17;LemieuxNeemeh syndrome;397 1.14.18;Leprosy;397 1.14.18.1;Clinical features;398 1.14.18.2;Investigation;398 1.14.18.3;Differential diagnosis;398 1
.14.18.4;Treatment and prognosis;399 1.14.19;Leptospirosis;399 1.14.20;Lesch-Nyhan disease;399 1.14.20.1;Clinical features;400 1.14.20.2;Investigation;400 1.14.20.3;Differential diagnosis;400 1.14.20.4;Treatment and prognosis;400 1.14.21;Leucoencephalopathy with neuroaxonal spheroids (LENAS);400 1.14.22;Leukodystrophies: overview;401 1.14.22.1;Differential diagnosis;401 1.14.23;Lewis Sumner syndrome;402 1.14.24;LhermitteDuclos disease;402 1.14.25;LiFraumeni syndrome (LFS) [OMIM#161523];403 1.14.26;Limb-girdle muscular dystrophies (LGMD): overview;403 1.14.26.1;Clinical features;406 1.14.26.2;Investigation;406 1.14.26.3;Differential diagnosis;406 1.14.26.4;Treatment and prognosis;406 1.14.27;Limbic encephalitis;406 1.14.28;Limb shaking;407 1.14.29;Locked-in syndrome;407 1.14.29.1;Clinical history;408 1.14.29.2;Investigation;408 1.14.29.3;Differential diagnosis;408 1.14.29.4;Treatment and prognosis;408 1.14.30;Long QT syndromes (LQTS);409 1.14.30.1;Clinical features;410 1.14.30.2;Investigation;410 1.14.30.3;Differential diagnosis;410 1.14.30.4;Treatment and prognosis;410 1.14.31;Long thoracic nerve palsy;410 1.14.32;Low back pain: overview;411 1.14.32.1;Clinical features;411 1.14.32.2;Investigation;412 1.14.32.3;Differential diagnosis;412 1.14.32.4;Treatment and prognosis;412 1.14.33;Luft disease;413 1.14.34;Lumbar cord and root disease: overview;413 1.14.34.1;Clinical features;413 1.14.34.2;Investigation;414 1.14.34.3;Differential diagnosis;414 1.14.34.4;Treatment and prognosis;414 1.14.35;Lumbosacral plexopathies;415 1.14.35.1;Clinical features;415 1.14.35.2;Investigation;415 1.14.35.3;Differential diagnosis;416 1.14.35.4;Treatment and prognosis;416 1.14.36;Lymphocytic hypophysitis;416 1.14.36.1;Clinical features;416 1.14.36.2;Investigation;416 1.14.36.3;Differential diagnosis;417 1.14.36.4;Treatment and prognosis;417 1.14.37;Lymphoma;417 1.14.37.1;Clinical features;417 1.14.37.2;Investigation;418 1.14.37.3;Differential diagnosis;418 1.14.37.4;Treatment and prognosi
s;418 1.14.38;Lysosomal storage disorders: overview;419 1.15;M;421 1.15.1;MachadoJoseph disease (MJD) [OMIM#109150];421 1.15.2;Malaria;421 1.15.2.1;Clinical features;422 1.15.2.2;Investigation;422 1.15.2.3;Differential diagnosis;422 1.15.2.4;Treatment and prognosis;422 1.15.3;Malignant hyperthermia [OMIM#145600];423 1.15.3.1;Clinical features;423 1.15.3.2;Investigation;423 1.15.3.3;Differential diagnosis;424 1.15.3.4;Treatment and prognosis;424 1.15.4;Malingering;424 1.15.5;Manganese poisoning, manganism;424 1.15.6;Marburg disease;425 1.15.7;MarchiafavaBignami syndrome;425 1.15.8;Marfan syndrome [OMIM#154700];426 1.15.8.1;Clinical features;426 1.15.8.2;Investigation;426 1.15.8.3;Differential diagnosis;426 1.15.8.4;Treatment and prognosis;427 1.15.9;Marin-Amat syndrome;427 1.15.10;MASA syndrome [OMIM#303350];427 1.15.11;Mast syndrome [OMIM#248900];428 1.15.12;McArdles disease [OMIM#232600];428 1.15.12.1;Clinical features;428 1.15.12.2;Investigation;429 1.15.12.3;Differential diagnosis;429 1.15.12.4;Treatment and prognosis;429 1.15.13;McLeods syndrome;429 1.15.14;Median neuropathy;430 1.15.14.1;Clinical features;430 1.15.14.2;Investigation;430 1.15.14.3;Differential diagnosis;431 1.15.14.4;Treatment and prognosis;431 1.15.15;Medication-overuse headache;431 1.15.16;Medulloblastoma;431 1.15.17;Meiges syndrome;432 1.15.17.1;Clinical features;432 1.15.17.2;Investigation;432 1.15.17.3;Differential diagnosis;432 1.15.17.4;Treatment and prognosis;433 1.15.18;Melanoma;433 1.15.19;MELAS syndrome;433 1.15.19.1;Clinical features;433 1.15.19.2;Investigation;434 1.15.19.3;Differential diagnosis;434 1.15.19.4;Treatment and prognosis;434 1.15.20;Melioidosis;435 1.15.21;MelkerssonRosenthal syndrome;435 1.15.22;Meningeal carcinomatosis;435 1.15.22.1;Clinical features;436 1.15.22.2;Investigation;436 1.15.22.3;Differential diagnosis;436 1.15.22.4;Treatment and prognosis;436 1.15.23;Meningioma;436 1.15.24;Meningitis: overview;437 1.15.24.1;Clinical features;438 1.15.24.2;Investigation;43
8 1.15.24.3;Differential diagnosis;438 1.15.24.4;Treatment and prognosis;439 1.15.25;Meningococcal disease;439 1.15.25.1;Clinical features;439 1.15.25.2;Investigation;440 1.15.25.3;Differential diagnosis;440 1.15.25.4;Treatment and prognosis;440 1.15.26;Meralgia paresthetica;441 1.15.26.1;Clinical features;441 1.15.26.2;Investigation;441 1.15.26.3;Differential diagnosis;441 1.15.26.4;Treatment and prognosis;441 1.15.27;MERRF syndrome;442 1.15.27.1;Clinical features;442 1.15.27.2;Investigation;442 1.15.27.3;Differential diagnosis;442 1.15.27.4;Treatment and prognosis;442 1.15.28;Metabolic storage disorders: overview;443 1.15.29;Metachromatic leukodystrophy (MLD);443 1.15.29.1;Clinical features;444 1.15.29.2;Investigation;444 1.15.29.3;Differential diagnosis;445 1.15.29.4;Treatment and prognosis;445 1.15.30;Metastatic disease and the nervous system: overview;445 1.15.30.1;Clinical features;446 1.15.30.2;Investigation;446 1.15.30.3;Differential diagnosis;446 1.15.30.4;Treatment and prognosis;446 1.15.31;Methanol poisoning;446 1.15.32;Migraine;447 1.15.32.1;Clinical features;447 1.15.32.2;Investigation;448 1.15.32.3;Differential diagnosis;448 1.15.32.4;Treatment and prognosis;449 1.15.33;Migralepsy;449 1.15.34;Mild cognitive impairment (MCI);450 1.15.34.1;Clinical features;450 1.15.34.2;Investigation;450 1.15.34.3;Differential diagnosis;450 1.15.34.4;Treatment and prognosis;450 1.15.35;Miller Fisher syndrome (MFS);451 1.15.35.1;Clinical features;451 1.15.35.2;Investigation;451 1.15.35.3;Differential diagnosis;451 1.15.35.4;Treatment and prognosis;452 1.15.36;Mills syndrome, Mills variant;452 1.15.37;Mitochondrial disease: overview;452 1.15.37.1;Clinical features;453 1.15.37.2;Investigation;454 1.15.37.3;Differential diagnosis;454 1.15.37.4;Treatment and prognosis;454 1.15.38;Mixed connective tissue disease (MCTD);455 1.15.39;Miyoshi myopathy [OMIM#254130];455 1.15.40;MNGIE syndrome;456 1.15.41;Möbius syndrome;457 1.15.42;MohrTranebjaerg syndrome [OMIM#304700];457 1.15.4
3;Mollaret meningitis;458 1.15.44;Monoclonal gammopathies;458 1.15.45;Monomelic amyotrophy;459 1.15.46;Mononeuritis multiplex: overview;459 1.15.47;Mortons metatarsalgia;460 1.15.48;Morvans syndrome;460 1.15.49;Motor neurone disease (MND);461 1.15.49.1;Clinical features;461 1.15.49.2;Investigation;462 1.15.49.3;Differential diagnosis;462 1.15.49.4;Treatment and prognosis;463 1.15.50;Motor neurone diseases: overview;463 1.15.51;Moyamoya;464 1.15.52;Mucormycosis;465 1.15.53;Multifocal motor neuropathy (MMN);465 1.15.53.1;Clinical features;466 1.15.53.2;Investigation;466 1.15.53.3;Differential diagnosis;466 1.15.53.4;Treatment and prognosis;467 1.15.54;Multi-minicore disease;467 1.15.55;Multiple sclerosis (MS);467 1.15.55.1;Clinical features;468 1.15.55.2;Investigation;468 1.15.55.3;Differential diagnosis;469 1.15.55.4;Treatment and prognosis;469 1.15.56;Multiple symmetric lipomatosis;470 1.15.57;Multiple system atrophy (MSA);470 1.15.57.1;Clinical features;471 1.15.57.2;Investigation;471 1.15.57.3;Differential diagnosis;472 1.15.57.4;Treatment and prognosis;472 1.15.58;Muscular dystrophies: overview;472 1.15.58.1;Investigation;473 1.15.59;Musculocutaneous neuropathy;473 1.15.59.1;Clinical features;474 1.15.59.2;Investigation;474 1.15.59.3;Differential diagnosis;474 1.15.60;Myasthenia gravis (MG);474 1.15.60.1;Clinical features;474 1.15.60.2;Investigation;475 1.15.60.3;Differential diagnosis;476 1.15.60.4;Treatment and prognosis;476 1.15.61;Mycoplasma;478 1.15.61.1;Clinical features;478 1.15.61.2;Investigation;478 1.15.61.3;Differential diagnosis;478 1.15.61.4;Treatment and prognosis;478 1.15.62;Myelopathy: overview;479 1.15.62.1;Clinical features;480 1.15.62.2;Investigation;480 1.15.63;Myoadenylate deaminase deficiency (MADD);481 1.15.64;Myoclonus-dystonia syndrome (MDS);481 1.15.65;Myopathy: overview;482 1.15.65.1;Clinical features;482 1.15.65.2;Investigation;482 1.15.65.3;Differential diagnosis;482 1.15.66;Myositis: overview;483 1.15.67;Myositis ossificans [OMIM#135
100];484 1.15.68;Myotonia congenita;484 1.15.68.1;Clinical features;484 1.15.68.2;Investigation;485 1.15.68.3;Differential diagnosis;485 1.15.68.4;Treatment and prognosis;485 1.15.69;Myotonic dystrophy type 1 (DM1) [OMIM#160900];485 1.15.69.1;Clinical features;486 1.15.69.2;Investigation;486 1.15.69.3;Differential diagnosis;487 1.15.69.4;Treatment and prognosis;487 1.15.70;Myotonic dystrophy type 2 (DM2) [OMIM#602668];487 1.15.70.1;Clinical features;488 1.15.70.2;Investigation;488 1.15.70.3;Differential diagnosis;488 1.15.70.4;Treatment and prognosis;488 1.15.71;Myotonic syndromes: overview;488 1.15.71.1;Investigation;489 1.15.71.2;Differential diagnosis;489 1.15.72;Myotubular/Centronuclear myopathies;490 1.16;N;491 1.16.1;Naegleria;491 1.16.2;Nevoid basal cell carcinoma syndrome;491 1.16.3;Narcolepsy;492 1.16.3.1;Clinical features;492 1.16.3.2;Investigation;493 1.16.3.3;Differential diagnosis;493 1.16.3.4;Treatment and prognosis;493 1.16.4;NARP syndrome;494 1.16.5;Nasu-Hakola disease;494 1.16.6;Nathalie syndrome;495 1.16.7;Neck-tongue syndrome;495 1.16.8;Necrotizing myelopathy;495 1.16.9;Nemaline myopathy;496 1.16.9.1;Clinical features;496 1.16.9.2;Investigation;496 1.16.9.3;Differential diagnosis;496 1.16.9.4;Treatment and prognosis;496 1.16.10;Neuralgic amyotrophy;497 1.16.10.1;Clinical features;497 1.16.10.2;Investigation;497 1.16.10.3;Differential diagnosis;498 1.16.10.4;Treatment and prognosis;498 1.16.11;Neuroacanthocytosis;498 1.16.11.1;Clinical features;499 1.16.11.2;Investigation;499 1.16.11.3;Differential diagnosis;500 1.16.11.4;Treatment and prognosis;500 1.16.12;Neuroblastoma;500 1.16.13;Neuroborreliosis;501 1.16.13.1;Clinical features;501 1.16.13.2;Investigation;502 1.16.13.3;Differential diagnosis;502 1.16.13.4;Treatment and prognosis;502 1.16.14;Neurobrucellosis;503 1.16.14.1;Clinical features;503 1.16.14.2;Investigation;503 1.16.14.3;Differential diagnosis;504 1.16.14.4;Treatment and prognosis;504 1.16.15;Neurocutaneous syndromes;504 1.16.16;Neurocy
sticercosis;505 1.16.16.1;Clinical features;506 1.16.16.2;Investigation;506 1.16.16.3;Differential diagnosis;506 1.16.16.4;Treatment and prognosis;506 1.16.17;Neurodegeneration with brain iron accumulation (NBIA);507 1.16.17.1;Clinical features;507 1.16.17.2;Investigation;507 1.16.17.3;Differential diagnosis;507 1.16.17.4;Treatment and prognosis;507 1.16.18;Neuroferritinopathy;508 1.16.19;Neurofibromatosis (NF);508 1.16.19.1;Clinical features;509 1.16.19.2;Investigation;509 1.16.19.3;Differential diagnosis;510 1.16.19.4;Treatment and prognosis;510 1.16.20;Neuroleptic malignant syndrome (NMS);510 1.16.20.1;Clinical features;511 1.16.20.2;Investigation;511 1.16.20.3;Differential diagnosis;511 1.16.20.4;Treatment and prognosis;511 1.16.21;Neuromuscular junction (NMJ) diseases: overview;512 1.16.22;Neuromyelitis optica (NMO);512 1.16.22.1;Clinical features;512 1.16.22.2;Investigation;513 1.16.22.3;Differential diagnosis;513 1.16.22.4;Treatment and prognosis;513 1.16.23;Neuronal ceroid lipofuscinosis (NCL): overview;514 1.16.24;Neuropathies: overview;514 1.16.24.1;Clinical features;517 1.16.24.2;Investigation;517 1.16.24.3;Differential diagnosis;518 1.16.24.4;Treatment and prognosis;518 1.16.25;Neurosarcoidosis;519 1.16.25.1;Clinical features;519 1.16.25.2;Investigation;520 1.16.25.3;Differential diagnosis;521 1.16.25.4;Treatment and prognosis;521 1.16.26;Neurosyphilis;522 1.16.26.1;Clinical features;522 1.16.26.2;Investigation;522 1.16.26.3;Differential diagnosis;523 1.16.26.4;Treatment and prognosis;523 1.16.27;Neurovascular compression syndromes: overview;523 1.16.28;NiemannPick disease (NPD) type C [OMIM#257220];524 1.16.28.1;Clinical features;524 1.16.28.2;Investigation;524 1.16.28.3;Differential diagnosis;525 1.16.28.4;Treatment and prognosis;525 1.16.29;NIFID;525 1.16.30;NMDA-receptor encephalitis;525 1.16.30.1;Clinical features;526 1.16.30.2;Investigation;526 1.16.30.3;Differential diagnosis;526 1.16.30.4;Treatment and prognosis;526 1.16.31;Nocardiosis;526 1.16.3
2;Nonaka myopathy [OMIM#605820];527 1.16.33;Non-epileptic attack disorder (NEAD);527 1.16.33.1;Clinical features;527 1.16.33.2;Investigation;528 1.16.33.3;Differential diagnosis;528 1.16.33.4;Treatment and prognosis;528 1.16.34;Non-Wilsonian hepatocerebral degeneration (NWHCD);529 1.16.35;Normal pressure hydrocephalus (NPH);529 1.16.35.1;Clinical features;530 1.16.35.2;Investigation;530 1.16.35.3;Differential diagnosis;531 1.16.35.4;Treatment and prognosis;531 1.16.36;Notalgia paresthetica;531 1.16.37;Numb and clumsy hands syndrome;532 1.16.38;Numb cheek syndrome, Numb chin syndrome;532 1.17;O;533 1.17.1;Obsessional slowness;533 1.17.2;Obstructive sleep apnea-hypopnea syndrome (OSAHS);533 1.17.2.1;Clinical features;534 1.17.2.2;Investigation;534 1.17.2.3;Differential diagnosis;534 1.17.2.4;Treatment and prognosis;535 1.17.3;Obturator neuropathy;535 1.17.3.1;Clinical features;535 1.17.3.2;Investigation;536 1.17.3.3;Differential diagnosis;536 1.17.4;Occipital neuralgia;536 1.17.5;Oculopharyngeal muscular dystrophy (OPMD);536 1.17.5.1;Clinical features;537 1.17.5.2;Investigation;537 1.17.5.3;Differential diagnosis;537 1.17.5.4;Treatment and prognosis;537 1.17.6;Oligodendroglioma;537 1.17.7;Ophthalmoplegic migraine;538 1.17.8;Optic neuritis;538 1.17.8.1;Clinical features;538 1.17.8.2;Investigation;539 1.17.8.3;Differential diagnosis;539 1.17.8.4;Treatment and prognosis;539 1.17.9;Orbital apex syndrome;540 1.17.9.1;Superior orbital fissure syndrome;540 1.17.10;Orbital tumors: overview;540 1.17.10.1;Clinical features;540 1.17.10.2;Investigation;541 1.17.10.3;Differential diagnosis;541 1.17.10.4;Treatment and prognosis;541 1.17.11;Ornithine transcarbamoylase (OTC) deficiency;541 1.17.12;Oromandibular dystonia;542 1.17.12.1;Lingual dystonia;542 1.17.13;Ortner syndrome;542 1.17.13.1;Cardiovocal syndrome;542 1.17.14;Ossification of the posterior longitudinal ligament (OPLL);542 1.17.14.1;Clinical features;542 1.17.14.2;Investigation;542 1.17.14.3;Differential diagnosis;543 1.
17.14.4;Treatment and prognosis;543 1.17.15;Osteogenesis imperfecta;543 1.17.16;Osteomalacia;544 1.17.17;OSullivanMcLeod syndrome;544 1.17.18;Overlap syndrome;544 1.18;P;545 1.18.1;Pagets disease;545 1.18.1.1;Clinical features;545 1.18.1.2;Investigation;545 1.18.1.3;Differential diagnosis;546 1.18.1.4;Treatment and prognosis;546 1.18.2;Painful legs and moving toes (PLMT);546 1.18.2.1;Clinical features;546 1.18.2.2;Investigation;547 1.18.2.3;Differential diagnosis;547 1.18.2.4;Treatment and prognosis;547 1.18.3;Pallido-pyramidal syndrome;547 1.18.4;Pancoast syndrome;548 1.18.4.1;Clinical features;548 1.18.4.2;Investigation;548 1.18.4.3;Differential diagnosis;548 1.18.4.4;Treatment and prognosis;548 1.18.5;Paragonimiasis;549 1.18.6;Paraneoplastic syndromes: overview;549 1.18.6.1;Clinical features;550 1.18.6.2;Investigation;550 1.18.6.3;Differential diagnosis;551 1.18.6.4;Treatment and prognosis;552 1.18.7;Paraproteinemic demyelinating neuropathy (PDN);552 1.18.7.1;Clinical features;552 1.18.7.2;Investigation;553 1.18.7.3;Differential diagnosis;553 1.18.7.4;Treatment and prognosis;553 1.18.8;Parasomnias;554 1.18.8.1;Clinical features;554 1.18.8.2;Investigation;554 1.18.8.3;Differential diagnosis;554 1.18.8.4;Treatment and prognosis;555 1.18.9;Parkinsonian syndromes, parkinsonism;555 1.18.9.1;Clinical features;555 1.18.9.2;Investigation;556 1.18.9.3;Differential diagnosis;556 1.18.9.4;Treatment and prognosis;556 1.18.10;Parkinsons disease (PD);557 1.18.10.1;Clinical features;557 1.18.10.2;Investigation;559 1.18.10.3;Differential diagnosis;559 1.18.10.4;Treatment and prognosis;559 1.18.11;Parkinsons syndrome;561 1.18.12;Paroxysmal dyskinesias;561 1.18.12.1;Clinical features;561 1.18.12.2;Investigation;562 1.18.12.3;Differential diagnosis;562 1.18.12.4;Treatment and prognosis;563 1.18.13;Paroxysmal hemicrania;563 1.18.14;Parry-Romberg syndrome;564 1.18.14.1;Clinical features;564 1.18.14.2;Investigation;564 1.18.14.3;Differential diagnosis;564 1.18.14.4;Treatment and progn
osis;564 1.18.15;Patent foramen ovale (PFO);565 1.18.16;Pavor nocturnus;565 1.18.17;Payne syndrome;566 1.18.18;Pelizaeus-Merzbacher disease (PMD) [OMIM#312080];566 1.18.18.1;Clinical features;566 1.18.18.2;Investigation;567 1.18.18.3;Differential diagnosis;567 1.18.18.4;Treatment and prognosis;567 1.18.19;Pellagra;567 1.18.19.1;Clinical features;568 1.18.19.2;Investigation;568 1.18.19.3;Differential diagnosis;568 1.18.19.4;Treatment and prognosis;568 1.18.20;Periodic paralysis (PP);569 1.18.20.1;Clinical features;569 1.18.20.2;Investigation;569 1.18.20.3;Differential diagnosis;570 1.18.20.4;Treatment and prognosis;570 1.18.21;Peripheral nerve hyperexcitability (PNH);570 1.18.21.1;Clinical features;571 1.18.21.2;Investigation;571 1.18.21.3;Differential diagnosis;571 1.18.21.4;Treatment and prognosis;572 1.18.22;Peroneal neuropathy;572 1.18.22.1;Clinical features;572 1.18.22.2;Investigation;573 1.18.22.3;Differential diagnosis;573 1.18.23;Picks disease;573 1.18.24;Pineal gland tumors;573 1.18.25;Piriformis syndrome;574 1.18.25.1;Clinical features;574 1.18.25.2;Investigation;574 1.18.25.3;Differential diagnosis;575 1.18.25.4;Treatment and prognosis;575 1.18.26;Pisa syndrome;575 1.18.27;Pituitary disease: overview;575 1.18.27.1;Clinical features;576 1.18.27.2;Investigation;577 1.18.27.3;Differential diagnosis;577 1.18.27.4;Treatment and prognosis;577 1.18.28;POEMS syndrome;577 1.18.28.1;Clinical features;578 1.18.28.2;Investigation;578 1.18.28.3;Differential diagnosis;578 1.18.28.4;Treatment and prognosis;578 1.18.29;Poliomyelitis;579 1.18.29.1;Clinical features;579 1.18.29.2;Investigation;580 1.18.29.3;Differential diagnosis;580 1.18.29.4;Treatment and prognosis;580 1.18.30;Polyarteritis nodosa (PAN);580 1.18.30.1;Clinical features;581 1.18.30.2;Investigation;581 1.18.30.3;Differential diagnosis;581 1.18.30.4;Treatment and prognosis;581 1.18.31;Polycythemia rubra vera (PRV);582 1.18.32;Polyglucosan body disease (PGB);582 1.18.32.1;Clinical features;582 1.18.32.2;Invest
igation;582 1.18.32.3;Differential diagnosis;583 1.18.32.4;Treatment and prognosis;583 1.18.33;Polymyalgia rheumatica (PMR);583 1.18.33.1;Clinical features;583 1.18.33.2;Investigation;584 1.18.33.3;Differential diagnosis;584 1.18.33.4;Treatment and prognosis;584 1.18.34;Polymyositis;585 1.18.34.1;Clinical features;585 1.18.34.2;Investigation;585 1.18.34.3;Differential diagnosis;585 1.18.34.4;Treatment and prognosis;586 1.18.35;Pompes disease [OMIM#232300];586 1.18.35.1;Clinical features;587 1.18.35.2;Investigation;587 1.18.35.3;Differential diagnosis;587 1.18.35.4;Treatment and prognosis;588 1.18.36;Porphyria;588 1.18.36.1;Clinical features;588 1.18.36.2;Investigation;589 1.18.36.3;Differential diagnosis;589 1.18.36.4;Treatment and prognosis;590 1.18.37;Posterior cortical atrophy (PCA);590 1.18.38;Posterior interosseous syndrome;591 1.18.39;Posterior reversible leukoencephalopathy syndrome (PRES);591 1.18.39.1;Clinical features;592 1.18.39.2;Investigation;592 1.18.39.3;Differential diagnosis;592 1.18.39.4;Treatment and prognosis;592 1.18.40;Posthypoxic syndromes;592 1.18.40.1;Clinical features;593 1.18.40.2;Investigation;593 1.18.40.3;Differential diagnosis;593 1.18.40.4;Treatment and prognosis;593 1.18.41;Postpolio syndrome;593 1.18.41.1;Investigation;594 1.18.41.2;Treatment and prognosis;594 1.18.42;Potassium-aggravated myotonia (PAM) [OMIM#608390];594 1.18.42.1;Clinical features;594 1.18.42.2;Investigation;595 1.18.42.3;Differential diagnosis;595 1.18.42.4;Treatment and prognosis;595 1.18.43;Pregnancy and the nervous system: overview;595 1.18.44;Primary angiitis of the central nervous system (PACNS);597 1.18.44.1;Clinical features;597 1.18.44.2;Investigation;597 1.18.44.3;Differential diagnosis;598 1.18.44.4;Treatment and prognosis;598 1.18.45;Primary headache associated with sexual activity (PHSA);599 1.18.45.1;Differential diagnosis and investigation;599 1.18.45.2;Treatment and prognosis;599 1.18.46;Primary lateral sclerosis (PLS);600 1.18.46.1;Clinical feature
s;600 1.18.46.2;Investigation;600 1.18.46.3;Differential diagnosis;600 1.18.46.4;Treatment and prognosis;601 1.18.47;Primary orthostatic tremor (POT);601 1.18.47.1;Clinical features;601 1.18.47.2;Investigation;601 1.18.47.3;Differential diagnosis;602 1.18.47.4;Treatment and prognosis;602 1.18.48;Primary systemic amyloidosis;602 1.18.49;Prion disease: overview;603 1.18.49.1;Clinical features;603 1.18.49.2;Investigation;603 1.18.49.3;Differential diagnosis;604 1.18.49.4;Treatment and prognosis;604 1.18.50;Progeria [OMIM#176670];604 1.18.51;Progressive ataxia and palatal tremor (PAPT);605 1.18.52;Progressive encephalomyelitis with rigidity and myoclonus (PERM);605 1.18.53;Progressive multifocal leukoencephalopathy (PML);606 1.18.53.1;Clinical features;606 1.18.53.2;Investigation;606 1.18.53.3;Differential diagnosis;607 1.18.53.4;Treatment and prognosis;607 1.18.54;Progressive myoclonus epilepsies (PME);607 1.18.55;Progressive non-fluent aphasia (PNFA);608 1.18.55.1;Clinical features;609 1.18.55.2;Investigation;609 1.18.55.3;Differential diagnosis;609 1.18.55.4;Treatment and prognosis;609 1.18.56;Progressive subcortical gliosis of Neumann (PSG);610 1.18.56.1;Clinical features;610 1.18.56.2;Investigation;610 1.18.56.3;Differential diagnosis;610 1.18.56.4;Treatment and prognosis;610 1.18.57;Progressive supranuclear palsy (PSP);611 1.18.57.1;Clinical features;611 1.18.57.2;Investigation;611 1.18.57.3;Differential diagnosis;612 1.18.57.4;Treatment and prognosis;612 1.18.58;Pronator teres syndrome;613 1.18.58.1;Clinical features;613 1.18.59;Pseudomigraine;613 1.18.60;Pseudoxanthoma elasticum (PXE);614 1.18.60.1;Clinical features;614 1.18.60.2;Investigation;614 1.18.60.3;Treatment and prognosis;614 1.18.61;Psittacosis;615 1.18.62;Psychiatric disorders and neurological disease: overview;615 1.18.62.1;Clinical features;615 1.18.62.2;Investigation;616 1.18.62.3;Differential diagnosis;616 1.18.62.4;Treatment and prognosis;616 1.18.63;Pure autonomic failure (PAF);617 1.18.63.1;Cli
nical features;617 1.18.63.2;Investigation;617 1.18.63.3;Differential diagnosis;618 1.18.63.4;Treatment and prognosis;618 1.19;Q;619 1.19.1;Q fever;619 1.19.2;Quail myopathy;620 1.20;R;621 1.20.1;Rabies;621 1.20.1.1;Clinical features;621 1.20.1.2;Investigation;621 1.20.1.3;Differential diagnosis;622 1.20.1.4;Treatment and prognosis;622 1.20.2;Radial neuropathy;622 1.20.2.1;Clinical features;623 1.20.2.2;Investigation;623 1.20.2.3;Differential diagnosis;623 1.20.3;Radiculopathies: overview;623 1.20.3.1;Clinical features;623 1.20.3.2;Investigation;624 1.20.3.3;Differential diagnosis;624 1.20.3.4;Treatment and prognosis;624 1.20.4;Radiotherapy-induced neurological disorders;624 1.20.4.1;Clinical features;624 1.20.4.2;Investigation;625 1.20.4.3;Differential diagnosis;625 1.20.4.4;Treatment and prognosis;625 1.20.5;Raeders paratrigeminal syndrome;625 1.20.5.1;Clinical features;626 1.20.5.2;Investigation;626 1.20.5.3;Differential diagnosis;626 1.20.5.4;Treatment and prognosis;626 1.20.6;Ramsay Hunt syndromes;627 1.20.7;Rasmussens encephalitis (RE), Rasmussens syndrome;627 1.20.7.1;Clinical features;627 1.20.7.2;Investigation;628 1.20.7.3;Differential diagnosis;628 1.20.7.4;Treatment and prognosis;628 1.20.8;Rapid-onset dystonia parkinsonism [OMIM#128235];628 1.20.9;Reflex epilepsies;629 1.20.10;Refsums disease;629 1.20.10.1;Clinical features;630 1.20.10.2;Investigation;630 1.20.10.3;Differential diagnosis;630 1.20.10.4;Treatment and prognosis;630 1.20.11;Relapsing polychondritis;631 1.20.12;REM sleep behavior disorder (REMBD);631 1.20.13;Renal disease and the nervous system: overview;632 1.20.13.1;Clinical features;632 1.20.13.2;Investigation;633 1.20.13.3;Differential diagnosis;634 1.20.13.4;Treatment and prognosis;634 1.20.14;Respiratory failure: overview;634 1.20.14.1;Clinical features;634 1.20.14.2;Investigation;635 1.20.14.3;Differential diagnosis;635 1.20.14.4;Treatment and prognosis;635 1.20.15;Restless legs syndrome (RLS);636 1.20.15.1;Clinical features;636 1.20.1
5.2;Investigation;636 1.20.15.3;Differential diagnosis;636 1.20.15.4;Treatment and prognosis;637 1.20.16;Reversible cerebral vasoconstriction syndromes (RCVS);637 1.20.16.1;Clinical features;638 1.20.16.2;Investigation;638 1.20.16.3;Differential diagnosis;638 1.20.16.4;Treatment and prognosis;638 1.20.17;Rhabdomyolysis;639 1.20.17.1;Clinical features;639 1.20.17.2;Investigation;639 1.20.17.3;Differential diagnosis;640 1.20.17.4;Treatment and prognosis;640 1.20.18;Rheumatoid arthritis;640 1.20.18.1;Clinical features;640 1.20.18.2;Investigation;641 1.20.18.3;Differential diagnosis;641 1.20.18.4;Treatment and prognosis;641 1.20.19;Rickettsial disease;642 1.20.19.1;Clinical features;642 1.20.19.2;Investigation;642 1.20.19.3;Differential diagnosis;642 1.20.19.4;Treatment and prognosis;642 1.20.20;Rigid spine syndrome [OMIM#602771];643 1.20.21;RileyDay syndrome [OMIM#223900];643 1.20.21.1;Investigation;644 1.20.21.2;Differential diagnosis;644 1.20.21.3;Treatment and prognosis;644 1.20.22;Rippling muscle disease (RMD) [OMIM#606072];644 1.20.23;RosaiDorfman disease;645 1.20.23.1;Clinical features;645 1.20.23.2;Investigation;645 1.20.23.3;Differential diagnosis;646 1.20.23.4;Treatment and prognosis;646 1.20.24;Ross syndrome;646 1.20.25;RoussyLévy syndrome [OMIM#180800];647 1.20.25.1;Clinical features;647 1.20.25.2;Investigation;647 1.20.25.3;Differential diagnosis;647 1.20.25.4;Treatment and prognosis;647 1.20.26;Rubella;648 1.20.27;Rucksack paralysis;648 1.21;S;649 1.21.1;Sandhoffs disease [OMIM#268800];649 1.21.2;Saphenous neuropathy;649 1.21.3;Sarcoglycanopathy;650 1.21.4;Satoyoshi syndrome;650 1.21.5;Scapuloperoneal syndrome;651 1.21.6;Scheuermanns disease;651 1.21.7;Schilders disease;651 1.21.7.1;Clinical features;652 1.21.7.2;Investigation;652 1.21.7.3;Differential diagnosis;652 1.21.7.4;Treatment and prognosis;653 1.21.8;Schistosomiasis;653 1.21.8.1;Clinical features;653 1.21.8.2;Investigation;654 1.21.8.3;Differential diagnosis;654 1.21.8.4;Treatment and prognosis;65
4 1.21.9;Schnitzlers syndrome;654 1.21.10;SchwartzJampel syndrome [OMIM#255800];654 1.21.10.1;Clinical features;655 1.21.10.2;Investigation;655 1.21.10.3;Differential diagnosis;655 1.21.10.4;Treatment and prognosis;655 1.21.11;Sciatic neuropathy;655 1.21.11.1;Clinical features;656 1.21.11.2;Investigation;656 1.21.11.3;Differential diagnosis;656 1.21.12;Sciatica;656 1.21.12.1;Clinical features;657 1.21.12.2;Investigation;657 1.21.12.3;Differential diagnosis;657 1.21.12.4;Treatment and prognosis;657 1.21.13;Scoliosis: overview;658 1.21.14;Semantic dementia (SD);658 1.21.14.1;Clinical features;659 1.21.14.2;Investigation;659 1.21.14.3;Differential diagnosis;659 1.21.14.4;Treatment and prognosis;659 1.21.15;Sengers syndrome;660 1.21.16;Septo-optic dysplasia;660 1.21.17;Serotonin syndrome;660 1.21.18;Shapiro syndrome;661 1.21.19;Shoulderhand syndrome;661 1.21.20;Sialidosis;661 1.21.20.1;Clinical features;662 1.21.20.2;Investigation;662 1.21.20.3;Differential diagnosis;662 1.21.20.4;Treatment and prognosis;663 1.21.21;Sickle-cell disease;663 1.21.22;Silver syndrome [OMIM#270685];663 1.21.23;Sjögrens syndrome;663 1.21.23.1;Clinical features;664 1.21.23.2;Investigation;664 1.21.23.3;Differential diagnosis;665 1.21.23.4;Treatment and prognosis;665 1.21.24;Sleep apnea syndromes: overview;665 1.21.25;Sleep disorders: overview;666 1.21.26;Sneddons syndrome;667 1.21.26.1;Clinical features;667 1.21.26.2;Investigation;667 1.21.26.3;Differential diagnosis;667 1.21.26.4;Treatment and prognosis;667 1.21.27;Solvent exposure;668 1.21.28;Somatoform disorders;668 1.21.29;Sparganosis;670 1.21.30;Spasmodic dysphonia;670 1.21.31;Spinal and bulbar muscular atrophy (SBMA) [OMIM#313200];670 1.21.31.1;Clinical features;671 1.21.31.2;Investigation;671 1.21.31.3;Differential diagnosis;671 1.21.31.4;Treatment and prognosis;671 1.21.32;Spina bifida;672 1.21.32.1;Clinical features;672 1.21.32.2;Investigation;672 1.21.32.3;Differential diagnosis;673 1.21.32.4;Treatment and prognosis;673 1.21.33;Spina
l cord disease: overview;673 1.21.33.1;Investigation;674 1.21.33.2;Differential diagnosis;674 1.21.34;Spinal cord vascular diseases;674 1.21.34.1;Clinical features;674 1.21.34.2;Investigation;675 1.21.34.3;Differential diagnosis;675 1.21.34.4;Treatment and prognosis;675 1.21.35;Spinal muscular atrophy (SMA);676 1.21.35.1;Clinical features;677 1.21.35.2;Investigation;677 1.21.35.3;Differential diagnosis;677 1.21.35.4;Treatment and prognosis;677 1.21.36;Spinal stenosis;678 1.21.36.1;Clinical features;678 1.21.36.2;Investigation;678 1.21.36.3;Differential diagnosis;679 1.21.36.4;Treatment and prognosis;679 1.21.37;Spinocerebellar ataxia (SCA);679 1.21.37.1;Differential diagnosis;682 1.21.38;Spontaneous intracranial hypotension (SIH);682 1.21.38.1;Clinical features;682 1.21.38.2;Investigation;682 1.21.38.3;Differential diagnosis;683 1.21.38.4;Treatment and prognosis;683 1.21.39;Spontaneous periodic hypothermia;683 1.21.40;Startle syndromes: overview;683 1.21.40.1;Clinical features;684 1.21.40.2;Investigation;684 1.21.40.3;Differential diagnosis;684 1.21.40.4;Treatment and prognosis;684 1.21.41;Status epilepticus;685 1.21.41.1;Clinical features;685 1.21.41.2;Investigation;685 1.21.41.3;Differential diagnosis;685 1.21.41.4;Treatment and prognosis;685 1.21.42;Stiffness: overview;686 1.21.42.1;Clinical features;687 1.21.42.2;Investigation;687 1.21.42.3;Differential diagnosis;688 1.21.42.4;Treatment and prognosis;688 1.21.43;Stroke: overview;688 1.21.43.1;Clinical features;689 1.21.43.2;Investigation;691 1.21.43.3;Differential diagnosis;691 1.21.43.4;Treatment and prognosis;691 1.21.44;Strongyloidiasis;692 1.21.44.1;Clinical features;692 1.21.44.2;Investigation;692 1.21.44.3;Differential diagnosis;693 1.21.44.4;Treatment and prognosis;693 1.21.45;Strychnine poisoning;693 1.21.45.1;Clinical features;693 1.21.45.2;Differential diagnosis;693 1.21.45.3;Treatment and prognosis;694 1.21.46;SturgeWeber syndrome;694 1.21.46.1;Clinical features;694 1.21.46.2;Investigation;695 1.21.46
.3;Differential diagnosis;695 1.21.46.4;Treatment and prognosis;695 1.21.47;Subacute combined degeneration of the spinal cord (SACDOC);695 1.21.48;Subacute motor neuronopathy;696 1.21.49;Subacute myelo-optic neuropathy (SMON);697 1.21.50;Subacute sclerosing panencephalitis (SSPE);697 1.21.50.1;Clinical features;697 1.21.50.2;Investigation;698 1.21.50.3;Differential diagnosis;698 1.21.50.4;Treatment and prognosis;698 1.21.51;Subarachnoid hemorrhage (SAH);698 1.21.51.1;Clinical features;699 1.21.51.2;Investigation;699 1.21.51.3;Differential diagnosis;700 1.21.51.4;Treatment and prognosis;700 1.21.52;Subclavian steal syndrome;701 1.21.53;Subdural empyema;702 1.21.53.1;Clinical features;702 1.21.53.2;Investigation;702 1.21.53.3;Differential diagnosis;702 1.21.53.4;Treatment and prognosis;702 1.21.54;Subdural hematoma (SDH);703 1.21.54.1;Clinical features;703 1.21.54.2;Investigation;703 1.21.54.3;Differential diagnosis;704 1.21.54.4;Treatment and prognosis;704 1.21.55;Subependymal giant-cell astrocytoma (SEGA);704 1.21.56;Sudden unexplained death in epilepsy (SUDEP);705 1.21.57;SUNCT syndrome, SUNA syndrome;705 1.21.57.1;Clinical features;705 1.21.57.2;Investigation;706 1.21.57.3;Differential diagnosis;706 1.21.57.4;Treatment and prognosis;706 1.21.58;Superficial siderosis of the central nervous system;706 1.21.58.1;Clinical features;706 1.21.58.2;Investigation;707 1.21.58.3;Differential diagnosis;707 1.21.58.4;Treatment and prognosis;707 1.21.59;Superior oblique myokymia;707 1.21.60;Susac syndrome;708 1.21.60.1;Clinical features;708 1.21.60.2;Investigation;708 1.21.60.3;Differential diagnosis;708 1.21.60.4;Treatment and prognosis;708 1.21.61;Sweets syndrome;709 1.21.62;Sydenhams chorea;709 1.21.62.1;Clinical features;710 1.21.62.2;Investigation;710 1.21.62.3;Differential diagnosis;710 1.21.62.4;Treatment and prognosis;710 1.21.63;Syncope;711 1.21.63.1;Clinical features;711 1.21.63.2;Investigation;712 1.21.63.3;Differential diagnosis;712 1.21.63.4;Treatment and prognosis
;712 1.21.64;Syndrome of inappropriate ADH secretion (SIADH);713 1.21.64.1;Clinical features;713 1.21.64.2;Investigation;713 1.21.64.3;Differential diagnosis;714 1.21.64.4;Treatment and prognosis;714 1.21.65;Synucleinopathy;714 1.21.66;Syringomyelia and syringobulbia;715 1.21.66.1;Clinical features;715 1.21.66.2;Investigation;716 1.21.66.3;Differential diagnosis;716 1.21.66.4;Treatment and prognosis;716 1.21.67;Systemic lupus erythematosus (SLE);716 1.21.67.1;Clinical features;717 1.21.67.2;Investigation;717 1.21.67.3;Differential diagnosis;718 1.21.67.4;Treatment and prognosis;718 1.21.68;Systemic sclerosis;718 1.21.68.1;Clinical features;719 1.21.68.2;Investigation;719 1.21.68.3;Differential diagnosis;719 1.21.68.4;Treatment and prognosis;719 1.22;T;720 1.22.1;Takayasus arteritis;720 1.22.1.1;Clinical features;720 1.22.1.2;Investigation;720 1.22.1.3;Differential diagnosis;720 1.22.1.4;Treatment and prognosis;721 1.22.2;Tangier disease [OMIM#205400];721 1.22.2.1;Clinical features;721 1.22.2.2;Investigation;721 1.22.2.3;Differential diagnosis;722 1.22.2.4;Treatment and prognosis;722 1.22.3;Tarlov cyst;722 1.22.4;Tauopathy;723 1.22.5;TaySachs disease [OMIM#272800];723 1.22.5.1;Clinical features;724 1.22.5.2;Investigation;724 1.22.5.3;Differential diagnosis;724 1.22.5.4;Treatment and prognosis;725 1.22.6;Teratoma;725 1.22.7;Tetanus;725 1.22.7.1;Clinical features;725 1.22.7.2;Sec21_20;726 1.22.7.3;Investigation;726 1.22.7.4;Differential diagnosis;726 1.22.7.5;Treatment and prognosis;726 1.22.8;Tethered cord syndrome;726 1.22.8.1;Clinical features;726 1.22.8.2;Investigation;727 1.22.8.3;Differential diagnosis;727 1.22.8.4;Treatment and prognosis;727 1.22.9;Thalamic syndromes: overview;727 1.22.9.1;Clinical features;727 1.22.9.2;Investigation;728 1.22.9.3;Differential diagnosis;728 1.22.9.4;Treatment and prognosis;728 1.22.10;Thoracic outlet syndromes (TOS);728 1.22.10.1;Clinical features;729 1.22.10.2;Investigation;729 1.22.10.3;Differential diagnosis;729 1.22.10.4;Trea
tment and prognosis;729 1.22.11;Thunderclap headache;730 1.22.11.1;Clinical features;730 1.22.11.2;Investigation;730 1.22.11.3;Differential diagnosis;730 1.22.11.4;Treatment and prognosis;731 1.22.12;Thyroid disease and the nervous system: overview;731 1.22.12.1;Clinical features;731 1.22.12.2;Investigation;732 1.22.12.3;Differential diagnosis;732 1.22.12.4;Treatment and prognosis;732 1.22.13;Tibial muscular dystrophy [OMIM#600334];733 1.22.14;Tibial neuropathy;733 1.22.14.1;Clinical features;733 1.22.14.2;Investigation;734 1.22.14.3;Differential diagnosis;734 1.22.15;TolosaHunt syndrome;734 1.22.16;Top of the basilar syndrome;735 1.22.16.1;Clinical features;735 1.22.16.2;Investigation;736 1.22.16.3;Differential diagnosis;736 1.22.16.4;Treatment and prognosis;736 1.22.17;Tourette syndrome (TS);736 1.22.17.1;Clinical features;737 1.22.17.2;Investigation;737 1.22.17.3;Differential diagnosis;737 1.22.17.4;Treatment and prognosis;737 1.22.18;Toxocariasis;738 1.22.19;Toxoplasmosis;738 1.22.19.1;Clinical features;738 1.22.19.2;Investigation;738 1.22.19.3;Differential diagnosis;739 1.22.19.4;Treatment and prognosis;739 1.22.20;Transient epileptic amnesia (TEA);739 1.22.20.1;Clinical features;739 1.22.20.2;Investigation;739 1.22.20.3;Differential diagnosis;740 1.22.20.4;Treatment and prognosis;740 1.22.21;Transient global amnesia (TGA);740 1.22.21.1;Clinical features;740 1.22.21.2;Investigation;740 1.22.21.3;Differential diagnosis;741 1.22.21.4;Treatment and prognosis;741 1.22.22;Transient ischemic attack (TIA);741 1.22.22.1;Clinical features;742 1.22.22.2;Investigation;742 1.22.22.3;Differential diagnosis;743 1.22.22.4;Treatment and prognosis;743 1.22.23;Transient unresponsiveness of the elderly;744 1.22.24;Transverse myelitis;744 1.22.24.1;Clinical features;745 1.22.24.2;Investigation;745 1.22.24.3;Differential diagnosis;745 1.22.24.4;Treatment and prognosis;745 1.22.25;Traumatic brain injury (TBI);746 1.22.25.1;Clinical features;746 1.22.25.2;Investigation;746 1.22.25.3;
Differential diagnosis;747 1.22.25.4;Treatment and prognosis;747 1.22.26;Tremor: overview;748 1.22.26.1;Clinical features;748 1.22.26.2;Investigation;749 1.22.26.3;Differential diagnosis;749 1.22.26.4;Treatment and prognosis;749 1.22.27;Trichinosis;750 1.22.27.1;Clinical features;750 1.22.27.2;Investigation;750 1.22.27.3;Differential diagnosis;751 1.22.27.4;Treatment and prognosis;751 1.22.28;Trigeminal autonomic cephalalagias (TACS): overview;751 1.22.29;Trigeminal neuralgia (TN);752 1.22.29.1;Clinical features;752 1.22.29.2;Investigation;752 1.22.29.3;Differential diagnosis;753 1.22.29.4;Treatment and prognosis;753 1.22.30;Trigeminal sensory neuropathy (TSN);753 1.22.31;Trinucleotide repeat diseases: overview;754 1.22.31.1;Investigation;756 1.22.31.2;Treatment and prognosis;756 1.22.32;Troyer syndrome;756 1.22.33;Trypanosomiasis;757 1.22.33.1;Clinical features;757 1.22.33.2;Investigation;758 1.22.33.3;Differential diagnosis;758 1.22.33.4;Treatment and prognosis;758 1.22.34;Tuberculosis (TB) and the nervous system: overview;758 1.22.34.1;Clinical features;759 1.22.34.2;Investigation;759 1.22.34.3;Differential diagnosis;759 1.22.34.4;Treatment and prognosis;759 1.22.35;Tuberculous meningitis (TBM);760 1.22.35.1;Clinical features;760 1.22.35.2;Investigation;761 1.22.35.3;Differential diagnosis;761 1.22.35.4;Treatment and prognosis;761 1.22.36;Tuberous sclerosis [OMIM#191100, #613254];762 1.22.36.1;Clinical features;762 1.22.36.2;Investigation;763 1.22.36.3;Differential diagnosis;763 1.22.36.4;Treatment and prognosis;763 1.22.37;Tumors: overview;763 1.22.37.1;Clinical features;764 1.22.37.2;Investigation;765 1.22.37.3;Differential diagnosis;765 1.22.37.4;Treatment and prognosis;765 1.22.38;Typhus;766 1.22.38.1;Clinical features;766 1.22.38.2;Investigation;766 1.22.38.3;Differential diagnosis;767 1.22.38.4;Treatment and prognosis;767 1.23;U;768 1.23.1;Ullrichs congenital muscular dystrophy [OMIM#254090];768 1.23.2;Ulnar neuropathy;768 1.23.2.1;Clinical features;769 1.2
3.2.2;Investigation;769 1.23.2.3;Differential diagnosis;769 1.23.2.4;Treatment and prognosis;770 1.23.3;UnverrichtLundborg disease [OMIM#254800];770 1.23.3.1;Clinical features;770 1.23.3.2;Investigation;770 1.23.3.3;Differential diagnosis;771 1.23.3.4;Treatment and prognosis;771 1.23.4;UrbachWiethe disease [OMIM#247100];771 1.23.5;Urea cycle enzyme defects (UCED): overview;772 1.23.5.1;Clinical features;773 1.23.5.2;Investigation;773 1.23.5.3;Differential diagnosis;773 1.23.5.4;Treatment and prognosis;774 1.23.6;Ushers syndromes;774 1.24;V;775 1.24.1;Van Buchems syndrome;775 1.24.2;Vanishing white matter disease (VWMD) [OMIM#603896];775 1.24.3;Variant CreutzfeldtJakob disease (vCJD);776 1.24.3.1;Clinical features;776 1.24.3.2;Investigation;776 1.24.3.3;Differential diagnosis;777 1.24.3.4;Treatment and prognosis;777 1.24.4;Varicella zoster virus (VZV) and the nervous system;777 1.24.5;Vascular dementia (VaD), vascular cognitive impairment (VCI);778 1.24.5.1;Clinical features;779 1.24.5.2;Investigation;779 1.24.5.3;Differential diagnosis;779 1.24.5.4;Treatment and prognosis;779 1.24.6;Vascular malformations: overview;780 1.24.7;Vasculitis;780 1.24.7.1;Clinical features;781 1.24.7.2;Investigation;781 1.24.7.3;Differential diagnosis;782 1.24.7.4;Treatment and prognosis;782 1.24.8;Vegetative states;782 1.24.8.1;Clinical features;783 1.24.8.2;Investigation;783 1.24.8.3;Differential diagnosis;783 1.24.8.4;Treatment and prognosis;783 1.24.9;Venous sinus thrombosis (VST);784 1.24.9.1;Clinical features;784 1.24.9.2;Investigation;784 1.24.9.3;Differential diagnosis;785 1.24.9.4;Treatment and prognosis;785 1.24.10;VergerDéjerine syndrome;785 1.24.11;Vernants disease;786 1.24.12;Vestibular neuritis;786 1.24.12.1;Clinical features;786 1.24.12.2;Investigation;786 1.24.12.3;Differential diagnosis;787 1.24.12.4;Treatment and prognosis;787 1.24.13;Vestibular paroxysmia;787 1.24.14;Vestibular schwannoma;788 1.24.14.1;Clinical features;788 1.24.14.2;Investigation;789 1.24.14.3;Differen
tial diagnosis;789 1.24.14.4;Treatment and prognosis;789 1.24.15;Visual loss: overview;790 1.24.16;Vitamin B12 deficiency;791 1.24.16.1;Clinical features;792 1.24.16.2;Investigation;792 1.24.16.3;Differential diagnosis;793 1.24.16.4;Treatment and prognosis;793 1.24.17;Vitamin deficiencies and the nervous system: overview;794 1.24.17.1;Clinical features;794 1.24.17.2;Investigation;794 1.24.17.3;Treatment and prognosis;795 1.24.18;VogtKoyanagiHarada (VKH) syndrome;795 1.24.18.1;Clinical features;795 1.24.18.2;Investigation;795 1.24.18.3;Differential diagnosis;796 1.24.18.4;Treatment and prognosis;796 1.24.19;Von HippelLindau (VHL) disease [OMIM#193300];796 1.24.19.1;Clinical features;796 1.24.19.2;Investigation;797 1.24.19.3;Differential diagnosis;797 1.24.19.4;Treatment and prognosis;797 1.24.20;Von WiniwarterBuergers disease;797 1.24.20.1;Clinical features;798 1.24.20.2;Investigation;798 1.24.20.3;Differential diagnosis;798 1.24.20.4;Treatment and prognosis;798 1.25;W;799 1.25.1;Wartenbergs neuropathy;799 1.25.1.1;Clinical features;799 1.25.1.2;Investigation;799 1.25.1.3;Differential diagnosis;799 1.25.1.4;Treatment and prognosis;799 1.25.2;WeberChristian disease;800 1.25.3;Wegeners granulomatosis;800 1.25.3.1;Clinical features;801 1.25.3.2;Investigation;801 1.25.3.3;Differential diagnosis;801 1.25.3.4;Treatment and prognosis;801 1.25.4;Welanders myopathy;802 1.25.5;WerdnigHoffmann disease [OMOM#253300];802 1.25.5.1;Clinical features;802 1.25.5.2;Investigation;803 1.25.5.3;Differential diagnosis;803 1.25.5.4;Treatment and prognosis;803 1.25.6;Werner syndrome [OMIM#277700];803 1.25.7;WernickeKorsakoff syndrome (WKS);804 1.25.7.1;Clinical features;804 1.25.7.2;Investigation;805 1.25.7.3;Differential diagnosis;805 1.25.7.4;Treatment and prognosis;805 1.25.8;Whipples disease;806 1.25.8.1;Clinical features;806 1.25.8.2;Investigation;806 1.25.8.3;Differential diagnosis;807 1.25.8.4;Treatment and prognosis;807 1.25.9;Wilsons disease [OMIM#277900];807 1.25.9.1;Clinical feat
ures;807 1.25.9.2;Investigation;808 1.25.9.3;Differential diagnosis;808 1.25.9.4;Treatment and prognosis;808 1.25.10;Wolfram syndrome;809 1.25.10.1;Clinical features;809 1.25.10.2;Investigation;810 1.25.10.3;Differential diagnosis;810 1.25.10.4;Treatment and prognosis;810 1.25.11;Writing tremor;810 1.25.12;Wyburn-Mason disease;811 1.26;XYZ;812 1.26.1;Xeroderma pigmentosum (XP);812 1.26.1.1;Clinical features;812 1.26.1.2;Investigations;813 1.26.1.3;Treatment and prognosis;813 1.26.2;X-linked dystonia-parkinsonism syndrome [OMIM#314250];813 1.26.3;X-linked myopathy with excessive autophagy (XMEA);814 1.26.4;Zinc deficiency;814